Alhemo
Drug
Novo Nordisk AS
Total Payments
$594,285
Transactions
4,573
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $594,285 | 4,573 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $594,285 | 4,573 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NN7415-4807 | Novo Nordisk AS | $131,664 | 0 |
| NN7415-4616 | Novo Nordisk AS | $130,882 | 0 |
| NN7415-4307 | Novo Nordisk AS | $100,359 | 1 |
| NN7415-4311 | Novo Nordisk AS | $40,622 | 0 |
Ad
Manufacturing Companies
- Novo Nordisk AS $594,285
Product Information
- Type Drug
- Total Payments $594,285
- Total Doctors 2
- Transactions 4,573
About Alhemo
Alhemo is a drug associated with $594,285 in payments to 2 healthcare providers, recorded across 4,573 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk AS.
Payment data is available from 2024 to 2024. In 2024, $594,285 was paid across 4,573 transactions to 2 doctors.
The most common payment nature for Alhemo is "Unspecified" ($594,285, 100.0% of total).
Alhemo is associated with 4 research studies, including "NN7415-4807" ($131,664).